A Protocol for the Inclusion of Minoritized Persons in Alzheimer Disease Research
From the ADNI3 Diversity Taskforce

Ozioma C. Okonkwo, PhD; Monica Rivera Mindt, PhD; Miriam T. Ashford, PhD; Catherine Conti, BA; Joe Strong, PhD; Rema Raman, PhD; Michael C. Donohue, PhD; Rachel L. Nosheny, PhD; Derek Flenniken, BS; Melanie J. Miller, PhD; Adam Diaz, MS; Annabelle M. Soto, BS; Beau M. Ances, MD, PhD; Maryam R. Beigi, MD; P. Murali Doraiswamy, MBBS; Ranjan Duara, MD; Martin R. Farlow, MD; Hillel T. Grossman, MD; Jacobo E. Mintzer, MD; Christopher Reist, MD; Emily J. Rogalski, PhD; Marwan N. Sabbagh, MD; Stephen Salloway, MD; Lon S. Schneider, MD; Raj C. Shah, MD; Ronald C. Petersen, MD, PhD; Paul S. Aisen, MD; Michael W. Weiner, MD; for the Alzheimer’s Disease Neuroimaging Initiative

Abstract

IMPORTANCE Black or African American (hereinafter, Black) and Hispanic or Latino/a/x (hereinafter, Latinx) adults are disproportionately affected by Alzheimer disease, but most research studies do not enroll adequate numbers of both of these populations. The Alzheimer’s Disease Neuroimaging Initiative-3 (ADNI3) launched a diversity taskforce to pilot a multipronged effort to increase the study inclusion of Black and Latinx older adults.

OBJECTIVE To describe and evaluate the culturally informed and community-engaged inclusion efforts to increase the screening and enrollment of Black and Latinx older adults in ADNI3.

DESIGN, SETTING, AND PARTICIPANTS This cross-sectional study used baseline data from a longitudinal, multisite, observational study conducted from January 15, 2021, to July 12, 2022, with no follow-up. The study was conducted at 13 ADNI3 sites in the US. Participants included individuals aged 55 to 90 years without cognitive impairment and those with mild cognitive impairment or Alzheimer disease.

EXPOSURES Efforts included (1) launch of an external advisory board, (2) changes to the study protocol, (3) updates to the digital prescreener, (4) selection and deployment of 13 community-engaged research study sites, (5) development and deployment of local and centralized outreach efforts, and (6) development of a community-science partnership board.

MAIN OUTCOMES AND MEASURES Screening and enrollment numbers from centralized and local outreach efforts, digital advertisement metrics, and digital prescreener completion.

RESULTS A total of 91 participants enrolled in the trial via centralized and local outreach efforts, of which 22 (24.2%) identified as Latinx and 55 (60.4%) identified as Black (median [IQR] age, 65.6 [IQR, 61.5-72.5] years; 62 women [68.1%]). This represented a 267.6% increase in the monthly rate of enrollment (before: 1.11 per month; during: 4.08 per month) of underrepresented populations. For the centralized effort, social media advertisements were run between June 1, 2021, and July 31, 2022, which resulted in 2079 completed digital prescreeners, of which 1289 met criteria for subsequent site-level screening. Local efforts were run between June 1, 2021, to July 31, 2022. A total of 151 participants underwent site-level screening (100 from local efforts, 41 from centralized efforts, 10 from other sources).

(continued)
CONCLUSIONS AND RELEVANCE  In this cross-sectional study of pilot inclusion efforts, a culturally informed, community-engaged approach increased the inclusion of Black and Latinx participants in an Alzheimer disease cohort study.

Introduction

Black or African American (hereinafter, Black) and Hispanic or Latinx/a/o (hereinafter, Latinx) older adults are more likely to develop Alzheimer disease (AD) and other dementias compared with non-Latinx White older adults.1-3 With some exceptions,4-15 most AD research has not created conditions that allow for equitable inclusion of populations most affected by AD inequities.4,16-33 Underinclusion has serious ethical and scientific implications, including limiting the external and internal validity of research, that perpetuate AD-related inequities. Underinclusion leads to a lack of generalizability of treatment trials, which may seriously affect the risks and benefits of approved treatments in underrepresented populations (URPs). Therefore, it is necessary to develop and evaluate approaches that will improve inclusion of URPs into AD research studies.

Community-engaged research (CER) is an evidence-based approach to improve the inclusion and engagement of URPs into clinical research.31,34 In CER, study teams work iteratively, collaboratively, and in equitable partnership with community-based organizations, community stakeholders, and community members. Researchers build and sustain relationships through co-learning and power sharing, earning and maintaining the trust of the community, and prioritizing giving back to the community first. This evidence-based approach has been underused by many AD investigators31,35,36 and has been primarily deployed in local in-person settings.

Like many other studies in the field, the Alzheimer’s Disease Neuroimaging Initiative (ADNI) historically has not equitably enrolled URPs.28,37 To address this issue, the ADNI3 Diversity Taskforce (DVTF) was established to deploy a culturally informed CER pilot study for increasing the inclusion of Black and Latinx older adults into ADNI3. Preliminary findings have been published.38 Herein we aim to more fully describe the efforts deployed as part of this pilot study and detail our results, including local and centralized outreach efforts, completion of a digital prescreener, full site-level screening and enrollment metrics, and characteristics of enrolled participants.

Methods

This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline. The ADNI3 was approved by the Advarra Independent Review Board. A signed informed consent form was obtained from all participants. Participants received financial compensation.

Description of Diversity Taskforce Efforts

The ADNI3 DVTF was launched on July 1, 2020, and concluded July 31, 2022, at the end of the ADNI3 funding cycle (eMethods 1 in Supplement 1 provides a brief description of the ADNI). It was led by 2 co-principal investigators (O.C.O. and M.R.M.) with expertise in brain health inequities and was established to (1) develop, implement, and assess pilot efforts to increase inclusion and engagement of older Black and Latinx adults; (2) publish ADNI data related to diversity and health inequities; and (3) generate health inequity aims for ADNI4. Multipronged efforts included (1) development and launch of the external advisory board (EAB) (eMethods 2 in Supplement 1), (2) changes to the ADNI3 protocol (eMethods 3 in Supplement 1), (3) modifications to the existing digital prescreener form, (4) selection and deployment of 13 ADNI3 sites to serve as DVTF sites (eMethods 4 in Supplement 1),
(5) development and deployment of culturally informed local and centralized outreach efforts (eFigure 1 in Supplement 1 provides an overview of DVTF inclusion pathways and efforts), and (6) establishment of the ADNI Community-Science Partnership Board (CSPB) (eMethods 5 in Supplement 1). Figure 1 shows a timeline of DVTF events. All materials for this effort were developed only in the English language. Information about ADNI3 study inclusion efforts before the DVTF efforts are included in eMethods 6 in Supplement 1.

Local Efforts
Local DVTF efforts were site-led and focused on in-person outreach and included some remote efforts. Local efforts were run between June 1, 2021, and July 31, 2022. The sites scaled up their efforts depending on their site demographic characteristics and prior experience. eTable 1 in Supplement 1 lists the 13 DVTF sites and principal investigators. The sites were asked to provide a brief summary about types of community-based organizations and the types and formats of outreach events.

Centralized Efforts
Centralized DVTF efforts focused on digital outreach. With feedback from the EAB, the DVTF commissioned a Latina-owned and operated marketing agency experienced with the engagement of URPs to create and launch culturally informed digital outreach efforts for each site. Efforts included site-specific social media advertisements and study inclusion micro-websites, which are site-specific webpages that appear after a potential participant clicks on the social media advertisement.

Social Media Efforts
Paid social media efforts were deployed on Facebook and Instagram between June 1, 2021, and July 31, 2022. eTable 2 in Supplement 1 reports the social media performance metrics and their respective definitions obtained from Facebook Analytics.

The advertisements were tailored to each site's location and goals (eg, based on the predominant ethnocultural identity in the site's proximity). The messaging and imagery were aligned with cultural values and beliefs that appealed to the respective URPs and was developed and informed by the expertise of the EAB, investigators, and marketing agency. The advertisements considered the audience's age, location, and interests (eg, music). Social media advertising techniques included remarketing (eg, when a visitor who has already interacted with online digital efforts is served an advertisement) and look-alike audiences (ie, advertisements are served to social media users who share similar characteristics with users who have previously interacted with those advertisements). Unique hyperlinks with urchin tracking modules to a site-specific microsite allowed data linkage from the advertisement to the digital prescreener.

Study Inclusion Micro-Websites
Individuals clicking social media advertisements were directed to site-specific micro-websites. Depending on site needs and demographic characteristics, up to 2 micro-websites focusing on Black...

---

Figure 1. Timeline of Alzheimer’s Disease Neuroimaging Initiative-3 (ADNI3) and Diversity Taskforce (DVTF) Efforts

<table>
<thead>
<tr>
<th>Event Description</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADNI3 (06/17-07/22)</td>
<td>June</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Screening &amp; enrollment before the start of DVTF efforts (06/17-03/20)</td>
<td>June</td>
<td>March</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Screening &amp; enrollment inactive due to COVID-19 (03/20-01/21)</td>
<td>May</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DVTF efforts underway (07/20-7/22)</td>
<td>March</td>
<td>July</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Screening &amp; enrollment during DVTF efforts (01/21-07/22)</td>
<td>January</td>
<td>July</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DVTF centralized efforts (social media advertisements) (05/21-7/22)</td>
<td>May</td>
<td>July</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
and/or Latinx communities were created (total of 20 unique micro-websites). Seven of the 13 sites had both Black- and Latinx-tailored micro-websites (n = 14), 5 had only Black-tailored micro-websites, and 1 had only a Latinx-tailored micro-website. The micro-websites were vetted by the study team and EAB. They included local branding and images designed to appeal to each site's URPs (images and language), as well as a link to a digital prescreener.

**Digital Prescreener**

Individuals who accessed the micro-websites were directed to complete a digital prescreener. The form was kept brief by asking only the most essential eligibility questions, with the aim of lowering potential barriers to study entry. It contained 2 main sections: contact form and eligibility form (Figure 2 shows prescreener flow and definitions). The information from completed prescreens was forwarded to the respective sites for further screening into ADNI3 or other studies. We captured the (1) number of completed contact forms in total and by microsite (Black- vs Latinx-tailored vs unknown, eg, instances where privacy settings scrubbed the urchin tracking modules from the URL), (2) number of completed eligibility forms, and (3) number of individuals deemed potentially eligible (meeting all eligibility criteria) (Figure 2), as well as the most common reasons for being deemed ineligible (multiple possible).

**Site-Level Screening and Enrollment Metrics**

We report screening and enrollment data from 2 sources, each of which captured unique information. The first was DVTF site reports. Available data included the number of site-level screened and enrolled participants by outreach source (local vs centralized). The second was the ADNI database at the University of Southern California Laboratory of Neuroimaging (LONI). Available data included the number of site-level screened individuals and those whose screening was unsuccessful, the overall and monthly URP enrollment, and characteristics of enrolled participants (eMethods 7 in Supplement 1 provides information about self-reported participant characteristics).

Data regarding screening and enrollment provided directly by the DVTF sites do not fully match those obtained from the LONI database. This discrepancy is not entirely unusual, as it occurs across

---

**Figure 2. Flow Diagram of the Alzheimer’s Disease Neuroimaging Initiative-3 (ADNI3) Diversity Taskforce (DVTF) Efforts Digital Prescreener**

- DVTF inclusion pathways into the ADNI3 study
- DVTF culturally informed outreach efforts
  - Local efforts
  - Centralized efforts
    - 25,833 Social media advertisement link clicks
    - 2,726 Completed digital prescreener contact forms
    - 2,079 Completed digital prescreener eligibility forms
    - 1,289 Individuals deemed eligible based on the digital prescreener
    - 100 Individuals underwent full in-clinic DVTF site screening
    - 73 Individuals enrolled at DVTF sites
  - 23 Individuals enrolled at DVTF sites
- Other inclusion sources
  - 41 Individuals underwent full in-clinic DVTF site screening
  - 2 Individuals enrolled at DVTF sites
all of ADNI and is partly due to the usual time lag between study visits and fully curated data entry in the LONI. In the future, greater effort would be made to reduce such discrepancies.

**Statistical Analysis**

Total URP screening frequencies and screen fail rates before and during DVTF efforts are reported. Total frequencies of advertisement metrics were tabulated for social media ads tailored to Black and Latinx adults. The Kruskal-Wallis test was used for continuous variables and Pearson $\chi^2$ test was conducted for categorical variables to evaluate differences in characteristics of participants enrolled before vs during the DVTF efforts. With 2-sided testing, the $\alpha$ level was set at .05, and $P$ values are provided without adjustment for multiplicity. All analyses were conducted using R, version 4.2 (R Foundation for Statistical Computing).39

**Results**

**Participant Characteristics**

A total of 91 participants enrolled in the trial via centralized and local outreach efforts. The median age of the enrolled participants was 65.6 (IQR, 61.5-72.5) years, 62 (68.1%) identified as female, 29 (31.9%) as male, 22 (24.2%) as Latinx, 8 (8.8%) as non-Latinx Asian, 55 (60.4%) as non-Latinx Black, 5 (5.5%) as non-Latinx White, and 1 (1.1%) as non-Latinx Other (from other ethnocultural groups). Compared with those enrolled before the DVTF efforts, participants enrolled during the efforts were younger (71.8 vs 65.6 years; $P < .001$) and included a higher percentage of Latinx (7.9% vs 24.2%) and non-Latinx Black (6.1% vs 60.4%) ($P < .001$) individuals (Table 1).

**Table 1. Characteristics of Participants Enrolled at DVTF Sites Before and During the DVTF Efforts**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Participants, No. (%)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total enrolled (N = 256)</td>
<td>Enrolled before DVTF efforts [06/17-03/20] (n = 165)</td>
</tr>
<tr>
<td>Age, median (IQR), y</td>
<td>70.0 (65.3-76.3)</td>
<td>71.8 (67.1-77.5)</td>
</tr>
<tr>
<td>Sex at birth</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>158 (61.)</td>
<td>96 (58.2)</td>
</tr>
<tr>
<td>Male</td>
<td>98 (38.3)</td>
<td>69 (41.8)</td>
</tr>
<tr>
<td>Ethnocultural identity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Latinx</td>
<td>35 (13.7)</td>
<td>13 (7.9)</td>
</tr>
<tr>
<td>Non-Latinx Asian</td>
<td>18 (7.0)</td>
<td>10 (6.1)</td>
</tr>
<tr>
<td>Non-Latinx Black</td>
<td>65 (25.4)</td>
<td>10 (6.1)</td>
</tr>
<tr>
<td>Non-Latinx White</td>
<td>134 (52.3)</td>
<td>129 (78.2)</td>
</tr>
<tr>
<td>Other non-Latinx$^d$</td>
<td>4 (1.6)</td>
<td>3 (1.8)</td>
</tr>
<tr>
<td>Education, median (IQR), y</td>
<td>16.0 (14.0-18.0)</td>
<td>16.0 (14.0-18.0)</td>
</tr>
<tr>
<td>Educational attainment group</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤12 y</td>
<td>26 (10.2)</td>
<td>19 (11.5)</td>
</tr>
<tr>
<td>&gt;12 y</td>
<td>230 (89.8)</td>
<td>146 (88.5)</td>
</tr>
<tr>
<td>Diagnosis group</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AD</td>
<td>22 (8.6)</td>
<td>17 (10.3)</td>
</tr>
<tr>
<td>CU</td>
<td>160 (62.5)</td>
<td>98 (59.4)</td>
</tr>
<tr>
<td>MCI</td>
<td>74 (28.9)</td>
<td>50 (30.3)</td>
</tr>
<tr>
<td>Family history of AD/dementia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>143 (56.5)</td>
<td>97 (59.5)</td>
</tr>
<tr>
<td>No</td>
<td>110 (43.5)</td>
<td>66 (40.5)</td>
</tr>
</tbody>
</table>

Abbreviations: AD, Alzheimer disease; CU, cognitively unimpaired; DVTF, Diversity Taskforce; MCI, mild cognitive impairment.

$^a$ Data are based on the University of Southern California Laboratory of Neuroimaging.

$^b$ $P$ values were determined using Kruskal-Wallis test.

$^c$ $P$ values were determined using Pearson $\chi^2$ test.

$^d$ Includes individuals self-reporting their ethnicity as not Hispanic/Latino and as either American Indian/Alaska Native, Native Hawaiian/Pacific Islander, or individuals who indicated more than 1 race or declined to answer.
Local Efforts
Based on the available data, local efforts used different types of community-based organizations and engaged in different types of outreach efforts (Table 3 in Supplement 1 provides counts). The 2 most common types of community-based organizations were senior centers and local clinics. In-person outreach efforts included presentations, booths, and presence at community-based organization events, celebrations, and health fairs. Other in-person efforts included support groups and caregiver training. The 2 most common remote outreach efforts were engagement on local radio and television and webinars via a video conference.

Centralized Efforts
A total of 198 advertisements were deployed, which reached 795,715 users (Table 2). There were 6771 reactions, 419 comments, 657 shares, and 226 saves. The links from the advertisements were clicked 25,833 times (1.1% click-through rate).

Digital Prescreening
Link clicks from the digital advertisements resulted in 2726 completed contact forms (Figure 3). Of those, tracking identified that 688 forms (25.2%) were from Black-tailed micro-websites, 614 (22.5%) were from Latinx-tailed micro-websites, and 1424 (52.2%) were from unknown sources. A total of 2079 participants went on to complete the prescreener form. Of those who completed the

Table 2. Social Media Campaign Metric Results

<table>
<thead>
<tr>
<th>Metric</th>
<th>Advertisements, No.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total (N = 198)</td>
</tr>
<tr>
<td>Amount spent, $</td>
<td>124 731.63</td>
</tr>
<tr>
<td>Impressions</td>
<td>2 398 149</td>
</tr>
<tr>
<td>Reach</td>
<td>795 715</td>
</tr>
<tr>
<td>Link clicks</td>
<td>25 833</td>
</tr>
<tr>
<td>Click-through rate, %</td>
<td>1.1</td>
</tr>
<tr>
<td>Reactions</td>
<td>6771</td>
</tr>
<tr>
<td>Comments</td>
<td>419</td>
</tr>
<tr>
<td>Shares</td>
<td>657</td>
</tr>
<tr>
<td>Saves</td>
<td>226</td>
</tr>
</tbody>
</table>

Figure 3. Results From Local and Centralized Outreach Efforts

ADNI3 indicates Alzheimer’s Disease Neuroimaging Initiative-3; DVTF, Diversity Taskforce.
screener form and reported race and ethnicity (n = 829), 425 individuals (51.3%) self-identified as Black, 145 (17.5%) self-identified as Latinx, and 95 (11.5%) self-identified as from other ethnocultural groups. Of the 2079 who completed the digital prescreener form, 1289 (62.0%) were deemed potentially eligible for ADNI. Among the 790 who were deemed potentially ineligible, the 3 most common reasons for ineligibility were (1) self-report of a serious or unstable medical illness diagnosis other than AD (n = 427), (2) not being aged 55 to 90 years (n = 300), and (3) having a pacemaker, other implanted medical device, metal fragments, or other foreign objects in the body (n = 289).

Site-Level Screening and Enrollment

Screening Data Reported by the DVTF Sites
According to data reported by DVTF sites, 151 participants were site-level screened (Figure 3). Of those, 100 (66.2%) came from local efforts, 41 (27.2%) from centralized digital efforts, and 10 (6.6%) from other sources (eg, participant referral, web search).

Screening Data According to the LONI Database
According to the data in the LONI database, before the DVTF efforts (June 19, 2017, to March 9, 2020), the DVTF sites screened 237 participants (approximately 7 per month), with 50 (21.1%) URPs. Thirteen of the 50 individuals were excluded after the screening, resulting in a screen exclusion rate of 26.0%. During the DVTF efforts (June 15, 2021, to July 12, 2022), 145 individuals were screened (approximately 8 per month), of which 128 (88.3%) were URPs. Twenty of the 128 URPs were excluded after the screening, resulting in a screen exclusion rate of 15.6%. Among the 108 URPs whose screening was successful, 18 did not enroll. eFigure 2 in Supplement 1 provides a flowchart of the screening and enrollment numbers.

Enrollment Data Reported by the DVTF Sites
The DVTF sites reported enrolling a total of 98 participants (Figure 3). Of those, 73 (74.5%) came from local efforts, 23 (23.5%) from centralized efforts, and 2 (2.0%) from other sources.

Enrollment Data According to the LONI Database
According to the LONI (eFigure 2 in Supplement 1), 96 participants (90 URPs [93.8%]) initially enrolled. Five discontinued their participation early, of which 4 were URPs. This resulted in 91 enrolled participants with available demographic data, of which 86 (94.5%) were URPs (Table 2). The rate of enrollment of URPs improved from 1.11 per month before to 4.08 during the DVTF efforts, a 267.6% increase.

Discussion

Major Findings
Overall, this cross-sectional study found that multipronged and culturally informed CER-based outreach efforts are a feasible and robust way of increasing the representation of URPs in an ongoing observational AD study. The first main finding was that local (in-person) and centralized (digital/social media) CER-based efforts were successful in connecting with individuals from Black and Latinx populations. This is evidenced by engagement with social media advertisements and micro-websites, prescreener completions, reduced URP screening exclusion rates, and the number of Black and Latinx participants who enrolled at sites. Despite a similar overall rate of participants screened before (approximately 7 per month) and during (approximately 8 per month) DVTF efforts, the DVTF efforts resulted in a higher percentage of URPs screened (50 of 237 individuals [21.1%] vs 128 of 145 individuals [88.3%]). The efforts were especially successful in increasing the percentage of enrolled Black participants. These findings add to the emerging literature related to in-person and digital CER-based outreach efforts as tools for increasing the engagement of URP older adults in AD.
In addition, the digital CER approach yielded comparable results in terms of social media metrics, for example, the click-through rate of our efforts (1.1%) is similar to the results of culturally informed social media inclusion efforts into an online registry (Brain Health Registry: 1.1%). The digital CER approach allows for high scalability, but whether the approach is also feasible and efficacious in other URP\s remains to be determined.

The second main finding was that local efforts resulted in more site-level screening and enrollment compared with centralized efforts. This highlights the crucial role of intensive local site-led efforts in connecting with the community for clinical studies. A previous study \textsuperscript{46} comparing local and social media inclusion and engagement efforts in AD research also found that in-person efforts were more successful in recruiting Black participants. However, the new centralized efforts required time to set up, thus ran for a shorter time and may not have been able to gain the same amount of recognition in communities that ongoing local efforts may have previously established. Furthermore, with our available data we could not compare the cost-effectiveness of local vs centralized efforts. However, social media inclusion and engagement efforts are potentially a useful addition to local efforts. While it remains unclear why only 41 of 1289 participants who were digitally prescreened underwent site-level screening, potential reasons include difficulties reaching participants, limited site staff capacity for leveraging the large numbers of digital referrals (eg, efforts began during the pandemic, and it took time for many sites to scale back up in their capacity to conduct in-person visits), and staff turnover (eg, referral emails sent to outdated site staff email addresses or received by yet-to-be-trained staff). In addition, some participants were excluded by additional site screening before full screening. In sum, this calls attention to the need to work more closely with sites to understand their capacity for digital referrals, a more robust digital prescreening process, and improved data capture for additional site screening. Our findings highlight the critical role of local efforts and that centralized digital efforts should be seen as an adjunct and not a replacement.

Lessons Learned

**URP Leadership and Staff With Health Inequities Expertise**

One strength of this study was that the DVTF co-leads (O.C.O. and M.R.M.) possessed expertise in brain health inequities, CER, inclusion science, and/or AD and dementia. Moreover, there was genuine support (money, time, and human capital) by the ADNI leadership to implement this resource-intensive effort and provide CER and cultural competence training to all stakeholders. These requisite experience, expertise, support, and training factors were imperative for both leadership and staff.

**Support and Reciprocal Communication With Study Sites**

As study sites often run multiple studies, establishing reciprocal communication and adequate support is crucial. The DVTF team had regular email and video conferences with the sites not only to provide support and training but also to address issues that arose (eg, referrals from the centralized efforts being sent to staff no longer working on the study). Communication is important to regularly gauge site capacity, which helps manage site workload and informs the budget for digital advertisement for respective sites. It is also necessary to regularly obtain feedback on processes from clinical sites and responsively adjust to issues.

**Planning and Budgeting for CER Efforts Ahead of Time**

There is a substantial amount of groundwork, resources, and cost associated with the development and implementation of CER outreach efforts. Researchers interested in similar efforts should consider this during the planning and budgeting of their grant proposals. It is important to carefully plan time and budget costs for hiring and training diverse scientists and staff, establishing and maintaining CSPBs, hiring a marketing agency, supporting community-based organizations, developing and running centralized and local outreach materials, and developing platforms that
integrate data from multiple efforts. It is essential to approach this work in a proactive and well-
resourced manner that spans beyond the cyclical nature of grant funding periods to support
communities (eg, providing psychoeducation, AD resources, and feedback about biomarker results),
which in turn helps increase trust and participation.

Robust Data Capture of Site Outreach Efforts
While efforts were made to collect outreach effort data from the sites, more robust data linkage
would be needed to more fully assess which efforts resulted in an enrollment and why. For example,
we were unable to connect certain outreach data (eg, whether participants were from local or
centralized efforts) to participant data in LONI. Improved data capture should include detailed
information on local and centralized efforts (including resources and costs) and prescreening, as well
as the ability to link outreach and prescreening data to in-clinic data. However, additional staff and
participant burden need to be considered.

Limitations
This pilot study was designed as a demonstration project, with a short timeframe for set-up and
execution, resulting in multiple limitations. Limitations arose from the cross-sectional and
nonexperimental design. Future studies should use longitudinal designs to examine the association
between efforts and engagement over time and a nuanced assessment of specific components and
intensity levels needed to yield desired outcomes. It is also notable that this effort was conducted
during a difficult and volatile time in the US (eg, COVID-19 pandemic and heightened awareness of
structural racism). Our pilot efforts were also not set up to collect all data necessary to connect the
costs and outcomes of different combinations of the multipronged approach to screening, reasons
for ineligibility, enrollment, and baseline participation results. Information about the total cost of
running the efforts is needed (eg, costs for creating and running the advertisements, commissioning
a marketing agency, investigator/staff to consult with the marketing agency, and cost of creating an
EAB and CSPB). The analysis focused on inclusion metrics (screening and enrollment) and future
studies should also evaluate engagement metrics, such as the completion of study procedures. The
study did also not collect any data on whether the DVTF sites continued their prior recruitment
efforts during the DVTF efforts period; future studies should assess and account for this.

Multiple selection biases affect the generalizability of the findings. For the digital efforts, this
includes a bias for individuals with access to technology, including the internet. Further, the digital
advertisements were not formally evaluated to estimate which concepts and messaging resonated
most with the communities. The DVTF efforts were guided by the EAB, which did not include lay
community members. The EAB evolved into the CSPB, which was established at the end of ADNI3.
The CSPB guides the ADNI4 efforts and includes lay community members to more fully implement
the ADNI CER approach and increase the diversity of perspectives. Furthermore, the DVTF efforts
focused on Black and Latinx adults without additional consideration of other intersectional
categories, such as years of education and socioeconomic status. Therefore, our sample may not be
representative of Black and Latinx individuals in the broader community, for example, in terms of
years of education, socioeconomic status, and health literacy. The enrollment of Latinx participants
may have been limited by both our lack of Spanish-language landing pages and the sites’ ability to
fully support Spanish-speaking participants. In ADNI4, we are expanding to other ethnocultural
groups (eg, American Indian or Alaska Native, Asian, and Native Hawaiian or Pacific Islander) and are
also facilitating the capacity of sites to fully engage Spanish-speaking participants. We are
additionally planning outreach to other URPs, such as people from lower socioeconomic
backgrounds, sexual and gender minorities, and rural dwellers. Because the integration of the DVTF
digital metrics into the existing ADNI3 data platform was limited, there was no systematic collection
of prescreen data prior to the efforts, and no data were collected on how protocol changes affected
URP enrollment. We recommend that future studies exercise diligence early in project planning to
ensure that tracking of data and metrics is fully optimized. The study limitations notwithstanding, the
success of this pilot effort provided the justification and impetus for the new Engagement Core in ADNI4\(^4\), which, as noted, is expanding CER efforts to all ADNI sites and to other URPs. In addition, the results might be applicable to inclusion efforts into non-AD research studies.

## Conclusions

In this cross-sectional study of pilot research inclusion efforts, we found initial evidence supporting a comprehensive multipronged culturally informed CER approach for increasing the inclusion of URPs into AD research. Much work remains to make AD research more inclusive, equitable, and valid. The new Engagement Core in ADNI4 is well-positioned to contribute to this effort by methodically leveraging the learnings from these pilot efforts.

---

**ARTICLE INFORMATION**

Accepted for Publication: June 4, 2024.

Published: August 9, 2024. doi:10.1001/jamanetworkopen.2024.27073

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2024 Okonkwo OC et al. *JAMA Network Open*.

**Corresponding Author:** Ozioma C. Okonkwo, PhD, Department of Medicine and Wisconsin Alzheimer’s Disease Research Center, University of Wisconsin School of Medicine and Public Health, 600 Highland Ave, J5/156 CSC MC2420, Madison, WI 53792 (ozioma@medicine.wisc.edu).

**Author Affiliations:** Department of Medicine and Wisconsin Alzheimer’s Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison (Okonkwo, Strong); Department of Psychology, Latin American Latinx Studies Institute, and African and African American Studies, Fordham University, Bronx, New York (Rivera Mindt); Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York (Rivera Mindt, Soto); Northern California Institute for Research and Education, Department of Veterans Affairs Medical Center, San Francisco (Ashford, Conti, Flenniken, Miller, Diaz, Weiner); VA Advanced Imaging Research Center, San Francisco Veteran’s Administration Medical Center, San Francisco, California (Ashford, Conti, Nosheny, Flenniken, Miller, Diaz, Weiner); Alzheimer’s Therapeutic Research Institute, University of Southern California, San Diego (Raman, Donohue, Aisen); Department of Psychiatry and Behavioral Sciences, University of California, San Francisco (Nosheny, Weiner); Department of Neurology, Washington University in Saint Louis, Saint Louis, Missouri (Ances); Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles (Beigi); Departments of Psychiatry and Medicine, Duke University School of Medicine, Durham, North Carolina (Doraswamy); Wein Center for Alzheimer’s Disease and Memory Disorders, Mount Sinai Medical Center, Miami Beach, Florida (Duara); Herbert Wertheim College of Medicine, Florida International University, Miami (Duara); Alzheimer’s Disease Research Center, University of Florida College of Medicine, Gainesville (Duara); Department of Neurology, Indiana University Health, Indianapolis (Farlow); The Alzheimer Disease Research Center, Mount Sinai School of Medicine, New York, New York (Grossman); Medical University of South Carolina, Ralph H. Johnson VA Healthcare Center, Charleston (Mintzer); MindX Sciences Inc, Indianapolis, Indiana (Reist); Science 37 Inc, Durham, North Carolina (Reist); Department of Psychiatry, University of California Irvine, Long Beach (Reist); Department of Neurology, University of Chicago, Chicago, Illinois (Rogalski); Alzheimer’s and Memory Disorders Division, Department of Neurology, Barrow Neurological Institute, Phoenix, Arizona (Sabbagh); Memory and Aging Program, Butler Hospital, Alpert Medical School, Brown University, Providence, Rhode Island (Salloway); Department of Psychiatry and Behavioral Sciences, Department of Neurology, Alzheimer’s Disease Research Center, Keck School of Medicine of USC, Los Angeles, California (Schneider); Department of Family and Preventive Medicine and the Rush Alzheimer’s Disease Center, Rush University Medical Center, Chicago, Illinois (Shah); Alzheimer’s Disease Research Center, Mayo Clinic College of Medicine, Rochester, Minnesota (Petersen); Department of Radiology and Biomedical Imaging, University of California, San Francisco (Weiner); Department of Medicine, University of California, San Francisco (Weiner); Department of Neurology, University of California, San Francisco (Weiner).

**Author Contributions:** Drs Okonkwo and Donohue had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Okonkwo, Rivera Mindt, and Ashford were co-first authors and contributed equally.

**Concept and design:** Okonkwo, Rivera Mindt, Conti, Strong, Nosheny, Soto, Mintzer, Sabbagh, Salloway, Aisen, Weiner.
Conflict of Interest Disclosures: Dr Okonkwo reported receiving grants from the National Institutes of Health (NIH) during the conduct of the study. Dr Ashford reported receiving grants from the National Institute on Aging (NIA) during the conduct of the study. Dr Raman reported receiving grants from the NIA during the conduct of the study. Dr Donohue reported receiving grants from the NIH during the conduct of the study and having a spouse who is a full-time employee of Janssen and receiving consulting fees from Roche outside the submitted work. Dr Nosheny reported receiving grants from the University of California, San Francisco, during the conduct of the study and grants from the NIH, California Department of Public Health, and Genentech Charitable Foundation outside the submitted work. Dr Beigi reported receiving grants from the University of California, Los Angeles, during the conduct of the study. Dr Doraiswamy reported receiving grants from the NIA to Duke University during the conduct of the study and grants from the Department of Defense, US Highbush Blueberry Council, Cure Alzheimer Fund, the NIH, Office of Naval Research, Lilly, Karen L. Wrenn Trust, and Salix; holding stock in Transposon, UMethod, Alzheon, Marvel Biome, and Evidation; and receiving personal fees from Lumos, Prospira, Keel Digital, AHEL, Otsuka, Nutricia, Sermo, and Compass outside the submitted work; in addition, Dr Doraiswamy had a patent for diagnosis and treatment of Alzheimer disease pending. Dr Grossman reported receiving grants from the NIA during the conduct of the study. Dr Mintzer reported receiving personal fees from the AARP Global Council on Brain Health as a consultant/governance committee member; the AARP Staying Sharp as a consultant/scientific advisor; Acadia as a consultant/advisory board member; AiOmed “Finder” as a consultant; nonfinancial support from the Alzheimer’s Therapeutic Research Institute as a committee member; being a Biopharma Connex majority owner; receiving consultant fees from Corium; receiving nonfinancial support from Elder Court as a steering committee member; receiving personal fees from Exciva as a scientific advisory board member; receiving consultant fees from Genentech; receiving nonfinancial support as a consultant from ICG Pharma; receiving nonfinancial support as a consultant/association member from the International Psychogeriatric Association; receiving consultant fees from Ironshore Pharmaceuticals and from Lundbeck, serving as a data safety and monitoring board member in the Nablone for Agitation Blinded Intervention Trial; holding stock in and serving as vice-president of clinical affairs of NeuroQuest; receiving consult fees from Otsuka and Praxis Bioresearch; serving as a staff physician at Ralph H. Johnson VA Health Care System, holding stock and serving as Managing Partner of Scientific Affairs at Recruitment; receiving consultant fees from Sumitomo Pharma Co Ltd and Sygnature Discovery; receiving nonfinancial support from Technology Accelerator Company as a board member, receiving support for specific clinical trials from the NIA, Alzheimer’s Association, Eisai Inc, Cerevel Therapeutics, LLC, the National Endowment for the Arts, Alzheimer’s Drug Discovery Foundation, Cognition Therapeutics Inc, Suven Life Sciences Ltd, and Vivoryon Therapeutics outside the submitted work. Dr Rogalski reported receiving grants from the NIA during the conduct of the study and grants from the NIA outside the submitted work. Dr Salloway reported receiving personal fees from Genentech/Roche, Eisai, Lilly, Novo Nordisk, Synaptogenix, Neurotherapia, Prothena, KeifeRx, Anavex, Signant, T3D, and CervoMed/EIP outside the submitted work. Dr Salloway reported receiving grants from Biogen, Lilly, Genentech, Roche, EISAI, and Janssen and consultant fees from Biogen, Lilly, Genentech, EISAI, Roche, Novo Nordisk, Acumen, Prothena, LabCorp, Abbvie, Alector, and Kisbee outside the submitted work. Dr Schneider reported receiving grants from the NIH, the California Department of Health Services, and the University of Southern California Alzheimer Disease Center during the conduct of the study. Dr Shah reported receiving grants paid to the Rush University Medical Center from the NIH during the conduct of the study and grants paid to Rush University Medical Center from Amylyx Pharmaceuticals Inc, Athira Pharma Inc, Edgewater NEXT, Eli Lilly & Co Inc, and Genentech Inc as site investigator for Alzheimer disease clinical trials outside the submitted work. Dr Petersen reported grants from NIH U19 AG024904 during the conduct of the study; and receiving grants from the NIH; consultant fees from Roche, Genentech Inc, Eli Lilly & Co Inc, and Nestle Inc; and serving as an unpaid consultant for Eisai Inc outside the submitted work. Dr Aisen reported receiving personal fees from Biogen, Merck, Roche, ImmunoBrain Checkpoint, and Abbvie and grants from Lilly, Eisai, and Alzheimer’s Association outside the submitted work. Dr Weiner reported receiving grants from the NIH.
National Institute of Neurological Disorders and Stroke and NIA from the Department of Defense. The California Department of Public Health, the University of Michigan, Siemens, Biogen, the Hillblom Foundation, the Alzheimer’s Association, Johnson & Johnson, Kevin and Connie Shanahan, GE, VUmc, the Australian Catholic University (HBI-BHR), the Stroke Foundation, and the Veterans Administration; consultant fees from Boxer Capital LLC, Cerecin Inc, Clario, the Dementia Society of Japan, Dolby Family Ventures, Eisai, Guidepoint, Health and Wellness Partners, Indiana University, LCN Consulting, MEDA Corp, Merck Sharp & Dohme Corp, NC Registry for Brain Health, Prova Education, T3D Therapeutics, the University of Southern California, and WebMD; speaking fees with travel funding from AD/PD Congress, Amsterdam UMC, Cleveland Clinic, CTAD, Foundation of Learning, Health Society (Japan), Kones, University of Pennsylvania, University of Toulouse, Japan Society for Dementia Research, the Korean Dementia Society, Merck Sharp & Dohme Corp, the National Center for Geriatrics and Gerontology (Japan), and the University of Southern California outside the submitted work; and Dr. Weiner serves on editorial boards for Alzheimer’s & Dementia and the Journal for Prevention of Alzheimer’s Disease. He has served on advisory boards for Acumen Pharmaceutical, Alzheon Inc, Cerecin, Merck Sharp & Dohme Corp, and NC Registry for Brain Health. He also serves on the University of Southern California ACT grant that receives funding from Eisai. He holds stock options with Alzeca, Alzheon Inc, ALZPath Inc, and Arven. No other disclosures were reported.

**Funding/Support:** Funding for the study was provided by the NIH NIA (grant U19 AG024904). Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (NIH grant U19 AG024904) and the Department of Defense ADNI (award W81XWH-12-2-0012). The ADNI is funded by the NIA, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association, Alzheimer’s Drug Discovery Foundation, Arclon Biotech, Bioclinica Inc, Biogen, Bristol-Myers Squibb Co, CereSpir Inc, Cogstate, Eisai Inc, Elan Pharmaceuticals Inc, Eli Lilly and Co, Euroimmun, F. Hoffmann-La Roche Ltd and its affiliated company Genentech Inc, Fujirebio, GE Healthcare, IXICO Ltd, Janssen Alzheimer Immunotherapy Research & Development LLC, Johnson & Johnson Pharmaceutical Research & Development LLC, Lumosity, Lundbeck, Merck & Co Inc, Meso Scale Diagnostics LLC, NeuroRx Research, Neurotrack Technologies, Novartis Pharmaceuticals Corp, Pfizer Inc, Piramal Imaging, Servier, Takeda Pharmaceutical Co, and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the NIH (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

**Role of the Funder/Sponsor:** The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Data Sharing Statement:** See Supplement 2.

**Additional Contributions:** Data used in preparation of this article were obtained from the ADNI database (http://adni.loni.usc.edu). We appreciate and acknowledge all supporters of the ADNI3 Diversity Task Force (DVTF) effort, including the entire ADNI leadership and all ADNI participants who contributed to this effort. The Foundation for the National Institutes of Health; Maria Carrillo, PhD, Carl Hill, PhD, and Heather Snyder PhD (The Alzheimer’s Association); The Alzheimer’s Therapeutic Research Institute team at the University of Southern California for their invaluable assistance, and all ADNI3 DVTF site staff. The DVTF External Advisory Board: Lisa Barnes, PhD (Rush University), Goldie Byrd, PhD (Wake Forest University), Dorothy Farrar-Edwards, PhD (University of Wisconsin-Madison), Carl Hill, PhD (The Alzheimer’s Association), Gladys Maestre, MD, PhD (University of Texas, Rio Grand Valley), and Donna Masterman (Prothena), PhD. Alanz Marketing: Roxanne Alanz, BA, Jennifer Source, BA, Luke Bair, BFA, Julian Hoover, BA, Lesley Van De Mortel, Joshua Moffitt, BA, Garrett Miller, MS (Alzheimer’s Therapeutic Research Institute, University of Southern California, San Diego) provided statistical support. Amber Niay, BS (Department of Medicine and Wisconsin Alzheimer’s Disease Research Center) provided graphic design support. None of the individuals received compensation for the preparation of this manuscript.

**Additional Information:** The website for the Alzheimer’s Disease Neuroimaging Initiative study at the University of Southern California Laboratory of Neuroimaging is available at http://adni.loni.usc.edu.

**REFERENCES**


Lee JY, Crooks RE, Pham T, et al. “If it helps someone, then I want to do it”: perspectives of persons living with dementia on research registry participation. *Dementia (London)*. 2019;1471301219827709.


SUPPLEMENT 1.
- eMethods 1. Brief Alzheimer’s Disease Neuroimaging Initiative Description
- eMethods 2. Alzheimer’s Disease Neuroimaging Initiative-3 Diversity Taskforce External Advisory Board
- eMethods 3. Changes to the Alzheimer’s Disease Neuroimaging Initiative-3 Protocol
- eMethods 4. Selection and Deployment of Diversity Taskforce Sites
- eMethods 5. Development of the Alzheimer’s Disease Neuroimaging Initiative Community-Science Partnership Board
- eMethods 6. ADNI3 Inclusion Efforts Before the DVTF Efforts
- eMethods 7. Participant Characteristics Metrics
- eTable 1. ADNI3 DVTF Sites and Principal Investigators
- eTable 2. Social Media Performance Metrics
- eTable 3. Counts of Types of Community-Based Organizations and Types of Outreach Efforts
- eFigure 1. Overview of the Diversity Taskforce Inclusion Pathways and Efforts
- eFigure 2. Diversity Taskforce Site Screening and Enrollment Flowchart
- eReferences

SUPPLEMENT 2.
- Data Sharing Statement